Маркеры воспаления и кардиоваскулярная патология при антифосфолипидном синдроме
Диссертация
На раннем этапе атерогенеза происходит поступление и накопление лейкоцитов в зоне воспаления, которое опосредуется взаимодействием между клеточными молекулами адгезии (КМА) (ICAM-1, VCAM-1, Е-селектин), расположенных на мембранах эндотелиальных клеток и лейкоцитов. В регуляции клеточных взаимодействий участвуют провоспалительные цитокины, экспрессирующиеся в зоне атеросклеротического повреждения… Читать ещё >
Список литературы
- Насонов E.JI. Антифосфолипидный синдром. — M.: Литера, 2004. 379с.
- Myakis S., Lockshin M.D., Atsumi Т. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome// J. Thromb. Haemost. 2006. — Vol. 4. — P. 295−306.
- Asherson R.A., Tikly M., Staub H. et al. Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies// Ann. Rheum. Dis. 1990. — Vol. 49. -P. 107−108.
- Yilmaz E., Adalet K., Yilmaz G. et al. Importance of serum anticardiolipin antibody levels in coronary heart disease// Clin. Cardiol. 1994. — Vol. 17. — P. 117−121.
- Vianna I.L., Khamashta M.A., Ordi-Ros J. et al. Comparision of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients// Am. J. Med. 1994. — Vol. 96. -P. 3−9.
- Chartash E.K., Lans D.M., Paget S.A. et al. Aortic insuffiency and mitral regurgitation in patients with systemic lupus erythematosus and antiphospholipid syndrome// Am. J. Med. 1989. — Vol. 86. — P. 407−412.
- Murphy J.J., Leach L.A. Findings at necroscopy in the heart of a patient with anticardiolipin syndrome// Br. Heart. J. 1989. — Vol. 62. — P. 61−64.
- Решетняк Т.М., Алекберова З. С., Александрова Е. Н. и др. Клинико-иммунологические аспекты антифосфолипидного синдрома// Вестник РАМН. 2003. — № 7. — С. 31−34.
- Ziporen L., Golberg N., Arod M. et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings inderformed heart valve// Lupus. 1996. -Vol. 5. — P. 196−205.
- Nesher G., Ilany J., Rosenmsnn D. et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment// Semin. Arthritis Rheum. 1997. — Vol. 27. -P. 27−35.
- Hojnik M., George J., Ziporen L. et al. Heart valve involvement (Libman-Sacs endocarditis) in the antiphospholipid syndrome// Circulation. — 1996. Vol. 93.-P. 1579−1587.
- Nihoyannopoulos P., Gomez P., Joshi M. et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies// Circulation. 1990. Vol. 82. — P. 369−375.
- Khamashta M.A., Cervera R., Asherson R.A. et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus//Lancet. 1990. — Vol. 335. — P. 1541−1544.
- Roldan C.A., Shively B.K., Lau C.C. et al. Systemic lupus erythematosus disease by transesofagealechocardiography and the role of antiphospholipid antibodies// J. Am. Coll. Cardiol. 1992. — Vol. 20. — P. 1127−1134.
- Gabriel F., Alcini E., Di Prima M.A. et al. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies// Int. J. Cardiol. 1995. — Vol. 51. -P. 117−126.
- Leung W-H., Wong K-L., Lau C-P. et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus// Am. J. Med. 1990. — Vol. 89. — P. 411−419.
- Cervera R., Font J., Pare С. et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients// Ann. Rheum. Dis. — 1992. -Vol. 51.-P. 156−159.
- Barbut D., Borer J.S., Gharavi A. et al. Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events// Am. J. Cardiol. 1992. Vol. 70. — P. 901−905.
- Tenedios F., Erkan D., Lockshin M.D. Cardiac involvement in the antiphospholipid syndrome// Lupus. 2005. — Vol. 14(9). — P. 691−696.
- Ford S.E., Charrette E.J., Knight J. et al. A possible role for antiphospholipid antibodies in acquired cardiac valve deformity// J. Rheumatol. — 1990. Vol. 17.-P. 1499−1503.
- Bercun Y., Elami A., Meir K. et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery// J.Thorac. Cardiovasc. Surg. 2004. — Vol. 127 (2). — P. 414−420.
- Manzi S., Meilahn E.N., Rairie J.E. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study// Am. J. Epidemiol. — 1997.-Vol. 145.-P. 408−415.
- Urowitz M.B., Gladman D.D., Ibanez D. et al. Modification of hypertension and hypercholesterolemia in patients with systemic lupus erythematosus: a quality improvement study// Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 115 121.
- Urowitz M.B., Ibanez D., Gladman D.D. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors// J. Rheumatol. — 2007. — Vol. 34.-P. 70−75.
- Petri M., Lakatta C., Magder L. et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis// Am. J. Med. 1994. — Vol. 96. -P. 254−259.
- Karrar A., Sequeira W., Block J.A. Coronary artery disease in systemic lupus erythematosus: a review of the literature// Semin. Arthritis. Rheum. 2001. — Vol. 30.-P. 436−443.
- Drenkard C., Villa A.R., Reyes E. et al. Vasculitis in systemic lupus erythematosus// Lupus. 1997. — Vol. 6. — P. 235- 242.
- Lazzerini P.E., Capecchi P.L., Selvi E. et al. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune disease?// Lupus. 2007. — Vol. 16 (11).-P. 852−863.
- Phadke K.V., Phillips R.A., Clarke D.T. et al. Anticardiolipin antibodies in ischemic heart disease: marker or myth?// Br. Heart. J. 1993. — Vol. 69. — P. 391−394.
- Sletness K.E., Smith P., Abdelnoor M. et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke// Lancet. 1992. — Vol. 339. — P. 451−453.
- De Caterina R., d’Ascanio A., Mazzone A. et al. Prevalence of anticardiolipin antibodies in coronary artery disease// Am. J. Cardiol. — 1990. — Vol. 65. — P. 922−923.
- Bick R.L., Baker W.F.Jr. Anticardiolipin antibodies and thrombosis// Hematol. Oncol. Clin. North. Am. 1992. — Vol. 6. — P. 1287−1299.
- Munoz-Rodriguez F.J., Font J., Cervera R. et al. Clinical study and follow-up of 100 patients with antiphospholipid syndrome// Semin. Arthritis. Rheum. — 1999.-Vol. 29.-P. 182−190.
- Krinic-Barrie S.O., O’Connor C.R., Looney S.W. et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis// Arch. Intern. Med. 1997. Vol. 157. — P. 2101−2108.
- Vaarala O., Manttari M., Manninen V. et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men// Circulation. 1995. — Vol. 91 (1). — P. 23−27.
- Diaz M.N., Becker R.C. Anticardiolipin antibodies in patients with unstable angina// Cardiology. 1994. — Vol. 84. — P. 380−384.
- Farsi A., Domeneghetti M.P., Fedi S. et al. High prevalence of anti-beta2-glycoprotein I antibodies in patients with ischemic heart disease// Autoimmunity. 1999. — Vol. 30. — P. 93−98.
- Veres K., Lakos G., Kereneyi A. et al. Antiphospholipid antibodies in acute coronary syndrome// Lupus. 2004. — Vol. 13. — P. 423−427.
- Bick R.L., Ismail Y., Baker W.F. et al. Coagulation abnormalities in patients with precocious coronary artery bypass grafting and precutaneus transcoronary angioplasty// Semin. J. Thromb. Hemost. 1993. — Vol. 19. — P. 411−417.
- Gavaghan T.P., Krilis S.A., Daggard G.E. et al. Anticardiolipin antibodies and occlusion of coronary bypass grafts// Lancet. 1987. — Vol. 2. — P. 977−978.
- Ciocca R., Choi J., Graham A. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery// Am. J. Surg. 1995. — Vol. 170. — P. 198−200.
- Jankowski M., Didek D., Dubiel J.S. et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome// Blood. Coagul. Fibrinolysis. 1998. — Vol. 9. — P. 753−756.
- Asherson R.A., Cervera R. Catastrophic antiphospholipid syndrome// Cur. Rheum. Reports. 2003. — Vol. 5. — P. 395−400.
- Gertner E., Leatherman J.W. Intracardiac mural thrombosis mimicking myxoma in the antiphospholipid syndrome// J. Rheumatol. — 1992. Vol. 19. -P. 1293−1298.
- The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia// Stroke. 1990. — Vol. 21. — P. 1268−1273.
- Lockshin M., Tenedios F., Petri M. et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report// Lupus. 2003. — Vol. 12. — P. 518−523.
- Насонов E.JI. Проблемы атеротромбоза в ревматологии// Вестник РАМН. -2003.-№ 7.-С. 6−11.
- Sailer Т., Vormittag R., Pabinger I. et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis// J. Rheumatol. 2005. — Vol. 32. — P. 462−468.
- Насонов Е.Л., Панюкова Е. В., Александрова Е. Н. и др. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные)// Кардиология. 2002. — № 42 (7). — С. 53−62.
- Вао С., Zhang С. Premature atherosclerosis in SLE patients: prevalence and risk factors// Lupus. The 8th International Congress on SLE. 2007. — Vol. 16. -P. 76−77.
- Angel A., Dixon I.M., Kirshenbaum L.A. et al. Biochemistry of Atherosclerosis. Manitoba, Canada: Springer Science Business Media, 2006. -579 p.
- Westerweel P. E., Luyten R. K., Koomans H. A. et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus// Arthritis Rheum. 2007. — Vol. 56 (5). — P. 1384−1396.
- Кондратьева Л.В., Роденска-Лаповок С.Г., Решетняк T.M. и др. Инфаркт миокарда и геморрагический альвеолит при системной красной волчанке// Консилиум. 2007. — № 9 (2). — С. 17−21.
- Попкова Т.В., Алекберова З. С. Насонов Е.Л. и др. Липид-белковые показатели системы транспорта холестерина крови у больных системной красной волчанкой в зависимости от антифосфолипидного синдрома// Научно-Практич. Ревматол.- 2001. № 5. — С. 12−18.
- Попкова Т.В., Алекберова З. С., Насонов Е. Л. и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке// Научно-Практич. Ревматол. — 2004. № 4. — С. 10−15.
- Jimenez S., Garcia-Criado М.А., Tassies D. et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome// Rheumatology (Oxford). 2005. — Vol. 44(6). — P. 756−761.
- Ames. P.R., Margarita. A., Sokoll K.B. et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data// Ann. Rheum. Dis. — 2005. Vol. 64 (2). — P. 315−317.
- Medina G., Casaos D., Jara L.J. et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome// Ann. Rheum. Dis. 2003. — Vol. 62 (7). — P. 607−610.
- Roch В., Kopprasch S., Pietzsch J. et al. Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus// Z. Rheumatol. -2004. Vol. 63 (4). — P. 331−337.
- Der H., Kerekes G., Veres K. et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome// Lupus. — 2007. Vol. 16 (7). — P. 497−503.
- Becarevic M., Andrejevic S., Miljic P. et al. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome// Clin. Exp. Rheumatol. 2007. — Vol. 25 (3). — P. 361−366.
- Margarita A., Batuca J., Scenna G. et al. Subclinical atherosclerosis in primary antiphospholipid syndrome// Ann. N. Y. Acad. Sci. 2007. — Vol. 1108. — P. 475−480.
- Vlachoyiannopoulos P.G., Kanellopoulos P.G., Ioannidis J.P.A. et al. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study// Rheumatology. — 2003. — Vol. 42.-P. 645−665.
- Bilora F., Boccioletti V., Girolami B. et al. Are antiphospholipid antibodies an independent risk factor for atheroslerosis?// Clin. Appl. Thromb. Hemost. — 2002.-Vol. 8.-P. 103−113.
- Maslowski L., McBane R., Alexewicz P. et al. Antiphospholipid antibodies in thromboangiitis obliterans// Vase. Med. 2002. — Vol. 7. — P. 259−264.
- Stale M., Poredos P., Peternel P. et al. Endothelial function is impaired in patients with primary antiphospholipid syndrome// Thromb. Res. 2006. -Vol. 118 (4).-P. 455−461.
- Falaschi F., Ravelli A., Martignoni A. et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus// Arthritis Rheum. 2000. — Vol. 43. — P. 1405−1409.
- Hanly J. G. Antiphospholipid syndrome: an overview// CMAJ. — 2003. — Vol. 168 (13).-P. 1675−1682.
- McMahon M., Grossman J., Chen W. et al. Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus// Lupus. — 2006. — Vol. 15. -P. 59−69.
- Pearson J. D. Normal endothelial cell function// Lupus. 2000. — Vol. 9 (3). -P. 183−188.
- Warkentin Т.Е., Aird W.C., Rand J.H. Sepsis, HIT and antiphospholipid syndrome. Hematology Am. Soc. Hematol. Educ. Program. 2003. — P. 497 519.
- Boor P.J., Yang Y., Gong B. Role of the media in vascular injury: atherosclerosis and dissection// Toxicol. Pathol. 2006. — Vol. 34. — P. 33−38.
- El-Magadmi M., Bodill H., Ahmad Y. et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunctional in women// Circulation. — 2004. Vol. 110 (4). — P. 399−404.
- Tedgui A. The role of inflammation in atherothrombosis: implications for clinical practice// Vase. Med. 2005. — Vol. 10 (1). — P. 45−53.
- Esper R.J., Nordaby R.A., Vilarino J.O. Endothelial dysfunction: a comprehensive appraisal// Cardiovasc. Diabetol. 2006. — Vol. 5. — P. 4−22.
- Cepinskas G., Wilson J.X. Inflammatory response in microvascular endothelium in sepsis: role of oxidants// J. Clin. Biochem. Nutr. — 2008. Vol. 42.-P. 175−184.
- Meroni P.L. Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus// Lupus. The 8th International Congress on SLE. -2007.-Vol. 16.-P. 17−19.
- Asherson R. A., Cervera R. Antiphospholipid antibodies and infections// Ann. Rheum. Dis. 2003. — Vol. 62. — P. 388−393.
- D’Crus D., Hughes G. Antibodies, thrombosis and the endothelium// Br. J. Rheum. 2000. — Vol. 30 (1). — P. 2−4.
- Pierangeli S.S., Espinola R.G., Liu X. et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin// Circ. Res. -2001. Vol. 88 (2). — P. 245−250.
- Pierangeli S.S., Harris E.N. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells// Lupus. 2003. — Vol. 12 (7). — P. 539−545.
- Amengual O., Atsumi Т., Khamashta M. A. Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium// Rheumatology. -2003.-Vol. 42.-P. 1029−1031.
- Ferrara D.E., Liu X., Espinola R.G. et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an In Vivo animal model// Arthritis Rheum. 2003. — Vol. 48 (11). — P. 3272−3279.
- Wallace D.J., Hahn B.H. Pathogenesis of Lupus. In Dubois' Lupus Erythematosus. 7th ed. Lippincott Williams & Wilkins, 2007. — P. 46 — 408.
- Belmont H.M., Abramson S.B., Lie J.T. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interaction of inflammatory cells and activaited endothelium// Arthritis Rheum. 1996. — Vol. 39 (1).- P. 9−22.
- Roubey RA. Mechanisms of autoantibody-mediated thrombosis// Lupus. -1998. Vol. 7 (Suppl 2).- P. 114−119.
- Meroni P.L., Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome// Curr. Opin. Rheumatol. 2001. — Vol. 13 (5). — P. 377−382.
- Fischetti F., Durigutto P., Pellis V. et al. Thrombus formation induced by antibodies to (32-glycoprotein I is complement dependent and requires a priming factor// Blood. 2005. — Vol. 106. — P. 2340−2346.
- Shamonki J.M., Salmon J.E., Hyjek E. et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies// Am. J. Obstet. Gynecol. 2007. — Vol. 196 (2). — P. 167−174.
- Pierangeli S.S. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome: lessons from In Vitro and In Vivo studies// Lupus. The 8th International Congress on SLE. 2007. — Vol. 16. — P. 19−20.
- Berman J., Girardi G., Salmon J.E. TNF-a is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss// J. Immunol. — 2005. Vol. 174. — P. 485−490.
- Giannakopoulos В., Passam F., Rahgozar S. et al. Current concepts on the pathogenesis of the antiphospholipid syndrome// Blood. 2007. — Vol. 109. -P. 422−430.
- Chen P.P. The novel autoantigens and prothrombotic mechanisms for antiphospholipid antibodies// Lupus. The 8th International Congress on SLE. -2007.-Vol. 16.-P. 20−22.
- Tousoulis D., Davies G., Stefanadis C. et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis// Heart. 2003. — Vol. 89 (9). — P. 993−997.
- Насонов E.JI. Васкулиты и васкулопатиии. Ярославль: «Верхняя Волга», 1999.-615с.
- George J., Blank М., Levy Y. et al. Differential effects of anti-(32-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome// Circulation. 1998. — Vol. 97. — P. 900−906.
- Matsuura E., Kobayashi K., Koike T. et al. Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome// Lupus. 2003. -Vol. 12.-P. 550−554.
- Farzaneh-Far A., Roman M.J., Lockshin M.D. et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus// Arthritis Rheum. 2006. — Vol. 54 (12). — P. 3918−3925.
- Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases// Circulation. — 2005. Vol. 112. — P. 33 373 347.
- Szekanecz Z., Shoenfeld Y. Lupus and cardiovascular disease: the facts// Lupus. 2006. — Vol. 15.-P. 3−10.
- Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein// Adv. Immunol. 1983.-Vol. 34.-P. 141−212.
- Gabay C., Kushnewr I. Acute-phase proteins and other systemic responses to inflammation // N. Engl. J. Med. 1999. — Vol. 340. — P. 448−454.
- Calabro P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells// Circulation.-2003.-Vol. 108.-P. 1930−1932.
- Jabs W.J., Logering B.A., Gerke P. et al. The kidney as a second site of human C-reactive protein formation in vivo// Eur. J. Immunol. 2003. — Vol. 33. — P. 152−161.
- Yasojima K., Schwab C., McGeer E.G. et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease// Brain Res. 2000. — Vol. 887. — P. 80−89.
- Dong Q., Wright J.R. Expression of C-reactive protein by alveolar macrophages//J. Immunol. 1996. — Vol. 156. — P. 4815−4820.
- Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention// Circulation. 2003. — Vol. 107. — P. 363 369.
- Насонов E. JL, Панюкова E. H., Александрова E. H. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные)// Кардиология. — 2002. № 7. — С. 53−59.
- Ridker P.M., Cushman М., Stampfer M.J. et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men// N. Engl. J. Med. -1997. Vol. 336. — P. 973−979.
- Ridker P.M., Hennekens C., Buring J.E. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women// N. Engl. J. Med. 2000. — Vol. 342. — P. 836−843.
- Wang T.J., Nam B.H., Wilson P.W.F. et al. Association of С reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study// Arterioscler. Thromb. Vase. Biol. — 2002. — Vol. 22. — P. 1662−1667.
- Ridker P.M., Rifai N., Pfeffer M.A. et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol And Recurrent Events (CARE) Investigator// Circulation. 1999. — Vol. 100. — P. 230−235.
- Taylor K.E., van den Berg C.W. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein// Immunology. 2007. — Vol. 120 (3). — P. 404−411.
- Oroszla’n M., Herczenik E., Rugonfalvi-Kiss S. et al. Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP// Int. Immunol. 2006. — Vol. 18 (6). — P. 871 878.
- Devaraj S., Davis В., Simon S. I. et al. CRP promotes monocyte-endothelial cell adhesion via Fc- receptors in human aortic endothelial cells under static and shear flow conditions// Am. J. Physiol. Heart. Circ. Physiol. — 2006. Vol. 291.-P. 1170−1176.
- Jialal I., Devaraj S., Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?// Hypertens. 2004. — Vol. 44. — P. 6−11.
- Szalai A.J., Alarcorn G.S., Calvo-Alern J. et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events// Rheumatology. — 2005. Vol. 44. — P. 864−868.
- Александрова A.E., Новиков А. А., Решетник T.M. и др. Клинико-иммунологическая оценка высокочувствительного метода определения С-реактивного белка при антифосфолипидном синдроме// Научно-Практич. Ревматол. 2007. — № 1. — С. 9−15.
- Pearson Т.А., Mensah G.A., Alexander R.W. et al. Markers of inflammation and cardiovascular disease-application to clinical and public health practice// Circulation. 2003. — Vol. 107. — P. 499−511.
- Pepys M.B., Lanham J.G., De Beer F.C. C-reactive protein in SLE// Clin. Reum. Dis. 1982. — Vol. 8. — P. 91−103.
- Al-Nammari S.S., Gulati V. Patel R. et al. Septic arthritis in haemodialysis patients: a seven-year multi-centre review// J. Orthop. Surg. (Hong Kong). -2008. Vol. 16 (1). — P. 54−57.
- Hannawi S., Haluska В., Marwick Т.Н. et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation// Arthritis Res. Ther. 2007. — Vol. 9 (6). — P. 116−125.
- Nakanishi H., Araki N., Kudawara I. et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma// Int. J. Cancer. — 2002.-Vol. 99 (2).-P. 167−170.
- Poredos P., Jezovnik M.K. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis// Int. Angiol. 2007. — Vol. 26 (4). -P. 306−311.
- Lee H.B., Pulido J.S., McCannel C.A. et al. Role of inflammation in retinal vein occlusion// Can. J. Ophthalmol. 2007. — Vol. 42 (1). — P. 131−133.
- Krieger E., van Der Loo В., Amann-Vesti B. et al. C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis// J. Vase. Surg. 2004. — Vol. 40 (4). — P. 644−649.
- Fox E.A., Kahn S.R. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies// Thromb. Haemost. -2005. Vol. 94 (2) — P. 362−365.
- Vigushin D.M., Pepys M.B., Hawkins P.N. Metabolic and scintigraphic studies of radioiodinat human C- reactive protein in health and disease// J. Clin. Invest. 1993.-Vol. 91.-P. 1351−1357.
- Williams R.C.Jr., Harmon M.E., Burlingame R. et al. Studies of serum C-reactive protein in systemic lupus erythematosus// J. Rheumatol. 2005. -Vol. 32.-P. 454−461.
- Burling F., Ng J., Thein H. et al. Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort// Lupus. 2007. — Vol. 16 (10). — P. 830−837.
- Barnes E.V., Narain S., Naranjo A. et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk// Lupus. 2005. — Vol. 14. — P. 576 582.
- Toloza S.M., Uribe A.G., McGwin G. Jr. et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events// Arthritis Rheum. 2004. — Vol. 50. — P. 3947−3957.
- Figueredo M.A., Podrigues A., Ruiz-Yague M. et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome// J. Rheumatol. — 2006. — Vol. 33. — P. 1980−1986.
- Ames P.R., Tommasino C., Brancaccio V. et al. C-Reactive protein in primary antiphospholipid syndrome// J. Rheumatol. 2007. — Vol. 34 (3). — P. 650 651.
- Miesbach W., Gilzinger A., Gokpinar B. et al. Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome// Immunobiology. 2005. — Vol. 210 (10). — P. 755−760.
- Twito O., Reshef Т., Ellis M.H. C-reactive protein level as a predictor of transient vs. sustained anticardiolipin antibody positivity// Eur. J.- Haematol. -2006. Vol. 76 (3). — P. 206−209.
- Kishimoto T. The biology of interleukin-6// Blood. 1989. — Vol. 74. — P. 110.
- Loppnow H., Werdan K., Buerke M. Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms// Innate Immun. 2008. — Vol. 14. — P. 63−87.
- Rajamannan N., Christman J., Foiles N. et al. Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway// J. Clin. Invest. — 2007. Vol. 117. — P. 2952 — 2961.
- Ridker P.M., Rifai N., Stampfer M.J. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men//Circulation.-2000.-Vol. 101.-P. 1767−1772.
- Cesari M., Penninx B.W., Newman A.B. et al. Inflammatory markers and cardiovascular disease (The health, aging and body composition health ABC. study)// Am. J. Cardiol. 2003. — Vol. 92. — P. 522- 528.
- Asanuma Y., Chung C.P., Oeser A. et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors// J. Rheumatol. — 2006. — Vol. 33 (3).-P. 445−447.
- Sabry A. A, Elbasyouni S.R., Kalil A.M. et al. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus// Nephrology (Carlton). 2006. — Vol. 11 (4). — P. 329−335.
- Tassies D., Espinosa G., Munoz-Rodrigues F.J. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome// Arthritis Rheum. — 2000. Vol. 43 (10). — P. 2349−2358.
- Sodin-Semrl S., Zigon P., Cucnik S. et al. Serum amyloid A in autoimmune thrombosis// Autoimmun. Rev. 2006. — Vol. 6 (1). — P. 21−27.
- Law W.G., Kong K.O., Chang H.H. et al. Improved control of disease activity in SLE is associated with downregulation of interferon inducible protein-10 (IP10. by statins// Lupus. The 8th International Congress on SLE. 2007. — Vol. 16.-P. 283.
- Avalos I., Chung C. P., Oeser A. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus// Lupus. — 2007. — Vol. 16 (12). -P. 981−986.
- Madan M., Bishayi В., Hoge M. et al. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model// Atherosclerosis. 2008. — Vol. 197 (2). — P. 504−514.
- Schieffer В., Selle Т., Hilfiker A. et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis// Circulation. — 2004. Vol. 110. — P. 3493−3500.
- Girn H.R.S., Orsi N.M., Homer-Vanniasinkam S. An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease// Vase. Med. 2007. — Vol. 12. — P. 299−309.
- Azzawi M., Hasleton P. Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease// Cardiovasc. Res.-1999.-Vol. 43.-P. 850−859.
- Kleemann R, Zadelaar S. and Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice// Cardiovasc. Res. — 2008. — Vol. 10. -P. 1093−1120.
- Kapadia S., Dibbs Z., Kurrelmeyer K. et al. The role of cytokines in the failing human heart// Cardiol. Clin. 1998. -Vol. 16. — P. 645−656.
- Taubman M.B., Fallon J.T., Schecter A.D. et al. Tissue factor in the pathogenesis of atherosclerosis// Thromb. Haemost. 1997. — Vol. 78. — P. 200−204.
- Haddy N., Sass C., Droesch S. et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort// Atherosclerosis. 2003. — Vol. 170. — P. 277−283.
- Ridker P.M., Rifai N., Pfeffer M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction// Circulation. 2000. — Vol. 101. — P. 2149−2153.
- Bruunsgaard H., Andersen-Ranberg K., Jeune B. Et al. A high plasma concentration of TNF-alpha is associated with dementia in centenarians// J. Gerontol. A Biol. Sci. Med. Sci. 1999. — Vol. 54. — P. M357−364.
- Elkind M.S., Cheng J., Boden-Albala B. et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis// Stroke. 2002. — Vol. 33. — P. 31−37.
- Manfredi A.A., Rovere P., Galati G. et al. Apoptotic cell clearance in systemic lupus erithemtosus. Opsonization by antiphospholipid antibodies// Arthritis Rheum. 1998. — Vol. 41 (2). — P. 205−214.
- Бородин А.Г., Баранов А. А., Клюквина Н. Г. и др. Клинико-патогенетическое значение фактора некроза опухоли-альфа1 при системной красной волчанке// Тер. Архив. 2002. — № 74 (5). — С. 32−35.
- May L-A., Huang Q., Morris D. et al. Relationship of tumour necrosis factora gene polymorphisms and neuropsychiatric lupus// Lupus. 2002. — Vol. 11.-P. 114−118.
- Wais Т., Fierz W., Stoll. T. et al. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission//J. Rheumatol. -2003. Vol. 30 (10). — P. 2133−2139.
- Кричевская О.А., Клюквина Н. Г., Александрова Е. Н. и др. Клиническое значение растворимых рецепторов фактора некроза опухоли альфа у больных системной красной волчанкой// Клин. Мед. 2004. — № 82 (10). — С. 51−55.
- Forastiero R.R., Martinuzzo М.Е., De Larranaga G.F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies// Lupus.-2005.-Vol. 14.-P. 129−136.
- Ильина A.E., Клюквина Н. Г., Александрова Е. Н. и др. Растворимые рецепторы а-фактора некроза опухолей: связь с атеросклеротическим поражением сосудов при системной красной волчанке у мужчин// Тер. Архив. 2006. — № 6. — С. 20−24.
- Sidiropoulos P.I., Karvounaris S.A., Boumpas D.T. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications// Arthritis Res. Ther. 2008. — Vol. 10 (3). — P. 207−216.
- Echtenacher В., Mannel D. N. Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis// J. Endotox. Res. -2002. Vol. 8 (5). — P. 365−369.
- Whitton P. S. Inflammation as a causative factor in the aetiology of Parkinson’s disease// Br. J. Pharmacol. 2007. — Vol. 150. — P. 963−976.
- Glen E. Foster, Marc J. Et al. Sleep apnoea & hypertension: physiological bases for a causal relation: intermittent hypoxia and vascular function: implications for obstructive sleep apnoea// Exp. Physiol. — 2007. — Vol. 92. — P. 51−65.
- Dourado V.Z., Tanni S.E., Vale S.A. et al. Systemic manifestations in chronic obstructive pulmonary disease// J. Bras. Pneumol. 2006.- Vol. 32 (2).- P. 161−171.
- Milioti N., Bermudez-Fajardo A., Penichet M.L. et al. Antigen-induced ummunomodulation in the pathogenesis of atherosclerosis// Clin. Develop. Immunol.-2008.-Vol. 10.-P. 1155−1170.
- Munoz L.E., van Bavel C., Franz S. et al. Apoptosis in the pathogenesis of systemic lupus erythematosus/ Lupus. 2008. — Vol. 17. — P. 371−375.
- Jacob H. Rand molecular pathogenesis of the antiphospholipid syndrome// Circ. Res. 2002. — Vol. 90. — P. 29−37.
- Aringer M., Smolen J. S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus// Arthritis Res. Ther. 2008. — Vol. 10. — P. 202−210.
- Hochberg M.C. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus// Arthritis Rheum. 1997. — Vol. 40. — P. 1725.
- Hughes G.R.V. Thrombosis, abortion, cerebral disease and lupus anticoagulant//BMJ. 1983. -Vol. 187. -P. 1088−1089.
- Насонова B.A. Системная красная волчанка. — M.: Медицина, 1972. — 248с.
- Bombardier С., Gladman D.D., Urowitz М.В. et al. Derivation of the SLEDAI (a disease activity index for lupus patients)// Arthritis Rheum. 1992. — Vol. 35.-P. 630−640.
- Gladman D.D., Ibanez D., Urowitz M.B. Systemic Lupus Erythematosus
- Disease Activity Index 2000// J. Rheumatol. 2002. — Vol. 29. — P. 288−291.
- Gladman D.D., Goldsmith C.H., Urowitz M.B. et al. The Systemic Lupus Erythematosus Collaborating Clinics / American College of Rheumatology index for systemic lupus erythematosus international comparison// J. Rheumatol. 2000. — Vol. 27. — P. 373−376.
- Голубев В.JI., Вейн A.M. Неврологические синдромы: Руководство для врачей. М.: Эйдос Медиа, 2002. — 832 с.
- Wilson P.W., D’Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories// Circulation. 1998. — Vol. 97. — P. 18 371 847.
- World Health Organization. International Society of Hypertension Guidelines for management of hypertension. Guidelines Subcommittee// J. Hypertens. — 1999.-Vol. 17.-P. 151−183.
- Hulley S., Grady D., Bush T. et al. Randomized trial of Estrogen Plus World Health Organization: Report of WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complication // Geneva, 1999.
- Bruce I.N. «Not only.but also»: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus// Rheumatology. 2005. — Vol. 44. — P. 1492−1502.
- Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)// Circulation. 2002. — Vol. 106. — P. 3143.
- Kannel W.B., Castelli W.P., McNamara M.P. The coronary profile: 12-year follow-up in Framingham Study / J. Occup. Med. 1987. — Vol. 9. — P. 611 619.
- Тихонова Т.Л., Мач Э.С., Широкова И. Е и др. Антифосфолипидный синдром и экзогенные факторы риска тромбозов// Тер. Архив. — 2004. № 76 (И).-С. 71−74.
- Перова Н.В. Суммарный коронарный риск ИБС и показания к лечению гиперхолестеринемии (применение Европейских рекомендаций к российским условиям)// Кардиология. 1996. — С. 49−53.
- Александрова Е.Л., Насонов Е. Л., Ковалев В. Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови// Клин. Ревматол. 1995. — № 4. — С. 35−39.
- Карпов Ю.А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения// Рефарм. — Москва, 2003. — С. 7−16.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертонии//Всероссийское научное общество кардиологов, 2002.
- Haward G., Sharrett A.R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators// Stroke. 1993. — Vol. 24. — P. 1297−1304.
- Kazmierski R., Watala C., Lukasik M. et al. Common carotid artery remodeling studied by sonomorphological criteria// J. Neuroimaging. — 2004. -Vol. 14(3).-P. 258−264
- Ianuzzi A., Michele M.D., Panico S. et al. Radical-Trapping Activity, Blood Pressure and Carotid Enlargement in women// Hypertension. 2003. — Vol.41. — P. 289−296.
- Дифференциальная диагностика нервных болезней. Руководство для врачей/ Под ред. Акимова Г. А., Одинака М. М. Спб.: Гиппократ, 2004. -744 с.
- Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the catastrophic antiphospholipid syndrome. Causes of death and prognostic factors in a series of 250 patients// Arthritis Rheum. 2006. — Vol. 54 (8). — P. 2568−2576.
- Cervera R., Piette J.-C., Font J. et al. Antiphospholipid Syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients// Arthritis Rheum. 2002. — Vol. 46 (4). — P. 1019−1027.
- Amigo M.C. The heart and APS// Clin. Rev. Allergy. Immunol. 2007. — Vol. 32 (2).-P. 178−183.
- Tincani A., Rebaioli С. В., Taglietti M. et al. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus// Rheumatology. 2006. — Vol. 45. — P. 8−13.
- Bili A., Moss A. J., Francis C. W. et al. Anticardiolipin antibodies and recurrent coronary events. A prospective study of 1150 patients// Circulation. -2000.-Vol. 102.-P. 1258−1263.
- Zuckerman E., Toubi E., Shiran A. et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study// Am. J. Med. 1996. — Vol. 171. — P. 381−386.
- Davies J.O., Hunt B.J. Myocardial infarction in young patients without coronary atherosclerosis: assume primary antiphospholipid syndrome until proved otherwise// Int. J. Clin. Pract. 2007. — Vol. 61 (3). — P. 379−384.
- Korkmaz C., Cansu D. U., Kasifoglu T. Myocardial infarction in young patients (<35 years of age) with systemic lupus erythematosus: a case report and clinical analysis of the literature// Lupus. 2007. — Vol. 16 (4). -P. 289 297.
- Sangle S. R., 'Cruz D. P. Syndrome X (angina pectoris with normal coronary arteries) and myocardial infarction in patients with anti-phospholipid (Hughes) syndrome// Lupus.- 2008. Vol. 17. — P. 83−85.
- Tanaseanu C., Moldoveanu E., Tanaseanu S. et al. Patients with primary antiphospholipid syndrome and coronary microvascular dysfunction distinct clinical subset// Rom. J. Intern. Med. — 2004. — Vol. 42. — P. 545−556.
- Turiel M., Muzzupappa S., Gottardi B. et al. Evaluation of cardiac abnormality and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography// Lupus. 2000. — Vol. 9. — P. 406112.
- Erdogan G., Goren M. Т., Diz Kucukkaya R. et al. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study// Stroke. 2005. — Vol. 36. — P. 592−596.
- Karim M.Y., Alba P., Tungekar M.F. et al. Hypertension as the presenting feature of the antiphospholipid syndrome// Lupus. 2002. — Vol. 11. — P. 253 -256.
- Godfrey Т., Khamashta M.A., Hughes G.R. Antiphospholipid syndrome and renal artery stenosis// QJM. 2000. — Vol. 93. — P. 127−129.
- Калашникова JI.A. Неврология антифосфолипидного синдрома. M: Медицина, 2003. — 256с.
- Nochy D., Daugas Е., Droz D. et al. The intrarenal vascular lesions associated with primary anti-phospholipid syndrome// J. Am. Soc. Nephrol. — 1999. -Vol. 10.-P. 507−518.
- Espinosa G., Cervera R., Font J. et al. The lung in the antiphospholipid syndrome// Ann. Rheum. Dis. 2002. — VI. 61. — P. 195−198.
- Shoenfeld Y., Harats D., Wick G. eds. Atherosclerosis And Autoimmunity. -Amsterdam Lausanne — New York — Oxford — Shannon — Singapure — Tokyo: ELSEVIER, 2001, 370p.
- Lorenz M.W., Von Kegler S., Steinmetz H. et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS)// Stroke. -2006.-Vol. 37.-P. 87−92.
- Jensen-Urstad K., Svenungsson E., de Faire U. et al. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease// Lupus. 2002. — Vol. 11. — P. 744−752.
- Doria A., Shoenfeld Y., Wu R. et al. Risk factors for subclinical atherosclerosis in a prospective cohorts of patients with systemic lupus erythematosus// Ann. Rheum. Dis. 2003. — Vol. 62. — P. 1071−1077.
- Manzi S., Selzer F., Sutton-Tyrrel K. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus// Arthritis Rheum. 1999. — Vol. 42 (1). — P. 51−60.
- Roman M.J., Salmon J.E., Spobel R. et al. Prevalence and correlates of accellerated atherosclerosis in systemic lupus erythematosus// N. Engl. J. Med. 2003. — Vol. 349. — P. 2399−2406.
- Boudier S.H.A. Arteriolar and capillary remodelling in hypertension// Drugs. -1999.-Vol. 59.-P. 37—40.
- Maisch B. Ventricular remodeling// Cardiology. 1996. — Vol. 87 (1). — P. 210.
- George F., Afek A., Gilburd S. et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies// Lupus. 1997. — Vol. 6. — P. 723−729.
- George F., Afek A., Gilburd S. et al. Induction of early athrosclerosis in LDL receptor deficient mice immunized with beta2 glycoprotein I// Circulation. — 1998.-Vol. 15.-P. 1108−1115.
- Gladman D.D., Urowitz M.B. Morbidity in systemic lupus erythematosus// J. Rheumatol. 1987. — Vol. 14 (13). — P. 223−226.
- Алекберова 3.C., Мач Э. С., Герасимова E.B. Состояние периферических артерий у больных системной красной волчанкой// Клин. Мед. — 2004. -№ 82 (4). С. 46−49.
- Petri М., Spence D., Hochberg М.С. Coronary artery disease risk factors in the John Hopkins Lupus Cohort: prevalence, recognition by patients, and preventing practices// Medicine. 1992. — Vol. 71. — P. 291−302.
- Vlachoyiannopoulos P.G., Kanellopoulos P.G., Ioannidis J.P. et al. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study// Rheumatology. — 2003. — Vol. 42.-P. 645−651.
- Urowitz M.B., Gladman D.D. How to improve morbidity and mortality in systemic lupus erythematosus// Rheumatology. 2000.- Vol. 39. — P. 238−244.
- Sherer Y., Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases// Nat. Clin. Pract. Rheumatol. — 2006. — Vol. 2. — P. 1—8.
- Shoenfeld Y., Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential// Arthritis Rheum. — 2005. Vol. 52 (9). — P. 2599−2606.
- Veres K., Lakos G., Kerernyi A. et al. Antiphospholipid antibodies in acute coronary syndrome// Lupus. 2004. — Vol. 13. — P. 423-^127.
- Baron M.A., Khamashta M.A., Hughes G.S. et al. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome// Ann. Rheum. Dis. 2005. — Vol. 64. — P. 144−146.
- Karvonen J., Paivansalo M., Kesaniemi Y.A. et al. Immunoglobulin M type of autoantibodies to ox-LDL has an inverse relation to carotid artery atherosclerosis// Circulation. 2003. — Vol. 108. — P. 2107−2112.
- Shoenfeld Y., Wu R., Dearing L. et al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?// Circulation. 2004. — Vol. 110.-P. 2552−1558.
- Shamsuzzaman A.S., Winnicki М., Lanfranchi P. et al. Elevated C-reactive protein in patients with obstructive sleep apnea// Circulation. — 2002. Vol. 105.-P. 2462−2464.
- Клюквина Н.Г., Баранов E.JL, Александрова Е. Н. и др. С-реактивный белок при системной красной волчанке у мужчин: связь с тромботическими осложнениям// Клин. Мед. — 1997. № 8. — С. 24−26.
- Svenungsson Е., Jensen-Urstad К., Heimbtirger М. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus// Circulation. 2001. -Vol. 104.-P. 1887−1893.
- Ильина A.E., Клюквина Н. Г., Александрова Е. Н. и соав. Атеросклеротическое поражение сосудов при системной красной волчанке и антифосфолипидном синдроме у мужчин. Научно-практич. Ревматол., 2005, 5,4−10
- Bobba R., Landolt-Marticorena С., Fortin P.R. Thrombosis and inflammation: a question in need of an answer. J. Rheumatol., 2005, 32 (3), 397−400
- Becker G. J., Waldburger M., Hughes G. R. et al. Value of C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann. Rheum. Dis., 1980, 39, 50−52-
- Morrow W. J., Isenberg D. A., Parry H. F. et al. C-reactive protein in sera from patients with systemic lupus erythematosus. J. Rheumatol., 1981, 8, 599−604
- Lee S-S., Singh S., Magder L. S. et al. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus, 2008, 17, 114−123
- Sponk P.E., Ter Borg E.J., Kallenberg C.G. Patients with systemic lupus erythematosus and Jaccoud" s arthropaty: a clinical subset with an increased С reactive protein response?// Ann. Rheum. Dis. 1992. — Vol. 52. — P. 358−361.
- Aringer M., Smolen J.S. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention// Lupus. 2004. — Vol. 13. — P. 344−347.
- Gustasfson G. Risk factors for atherosclerosis in SLE// Lupus. The 8th International Congress on SLE. 2007. — Vol. 16. — P. 293.
- Egerer K., Feist E., Rohr U. et al. Increased serum soluble CD 14, ICAM-1 and E-selectin correlated with disease activity and prognosis in systemic lupus erythematosus// Lupus. 2000. — Vol. 9. — P. 614−621.
- Sari R.A., Taysi S., Erdem F. et al. Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus// Rheumatol. Int. 2002. — Vol. 21 (4). — P. 149−152.
- Pierangeli S.S., Colden-Stanfield M., Liu X. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo// Circulation. 1999. — Vol. 99. — P. 1997−2002.